ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04904406 (Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection), which is not on this map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1
Who cites it
113 citing papers in PubMed, 190 citations in OpenAlex.
- Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.Open forum infectious diseases · 2025Trial
- Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial.AIDS and behavior · 2025Trial
- Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort.Infectious disease reports · 2026Article
- Dolutegravir population pharmacokinetics in racially, sex- and age-diverse and antiretroviral therapy-experienced adults with HIV in the United States.HIV medicine · 2026Article
- Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV on Any Antiretroviral Therapy Regimen: The Retrospective ESSENTIAL Study.Infectious diseases and therapy · 2026Article
- A distinct form of fat fibrosis is linked to insulin resistance in people with HIV.JCI insight · 2026Observational
- Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women with HIV.AIDS (London, England) · 2026Article
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity.Infectious diseases and therapy · 2026Article
- Longitudinal Serum Metabolomic Signatures Related to Integrase Strand Transfer Inhibitors-Associated Weight Gain in Women with HIV Enrolled in the MACS/WIHS Combined Cohort Study.The Journal of infectious diseases · 2026Article
- Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.The lancet. HIV · 2026Article
- Observational
- Altered Lipid and Neurotransmitter Metabolism as Potential Mechanisms of Weight Gain in Women With HIV Initiating INSTIs in a Pilot Study.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments.Current HIV/AIDS reports · 2026Review
- Type 2 diabetes in people living with HIV: epidemiology, mechanisms, sex differences and early-life determinants.Frontiers in endocrinology · 2026Review
- Article
- Longitudinal Weight Gain Trajectories After Initiation of Dolutegravir-Based Antiretroviral Therapy: A Retrospective Cohort Study.AIDS research and treatment · 2026Article
- Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients.Microorganisms · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundTreatment initiation with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain. Whether similar gains are seen after switch to INSTIs among virologically suppressed persons is less clear. We assessed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322).
methodsParticipants who were in follow-up from 1997-2017 and switched to INSTI-based antiretroviral regimens were included. Piecewise linear mixed-effects models adjusting for age, sex, race/ethnicity, baseline BMI, nadir and current CD4+ T-cell count, smoking, diabetes and follow-up time with suppressed HIV-1 RNA examined weight and waist circumference change before and after first switch to INSTIs. Linear spline models with a single knot at time of switch accounted for nonlinear trends.
resultsThe 972 participants who switched to INSTIs were 81% male and 50% nonwhite with a median age at switch of 50 years, CD4+ T-cell count 512 cells/μL, and BMI 26.4 kg/m2. Restricting to persons with suppressed HIV-1 RNA at switch (n = 691), women, blacks, and persons ≥60 years experienced greater weight gain in the 2 years after versus before switch. In adjusted models, white or black race, age ≥60, and BMI ≥30 kg/m2 at switch were associated with greater weight gain following switch among women; age ≥60 was the greatest risk factor among men. Trends for waist circumference were similar.
conclusionsYearly weight gain increased following switch to INSTIs, particularly for women, blacks, and persons aged ≥60. Concomitant increases in waist circumference suggest that this weight gain is associated with an increase in fat mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.